Canadian Pricing Body Sharpens Its Teeth

Companies doing business in Canada are likely to see new action to drive down medicine prices. Concerned by spiraling drug prices and its place in an increasingly complex pricing and reimbursement environment, the Patented Medicine Prices Review Board (PMPRB) has published a new three-year strategic plan which will address how it can better contribute to lower prices and sustainable healthcare, although nearer-term measures could be on the cards too.